<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACULAR - ketorolac tromethamine solution/ drops </strong><br>STAT Rx USA LLC<br></p></div>
<h1>ACULAR<span class="Sup">®</span><br>(ketorolac tromethamine ophthalmic solution) 0.5%<br>sterile
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s2"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION
</h1>
<p class="First"><span class="Bold">ACULAR</span><span class="Sup">®</span> (ketorolac tromethamine ophthalmic solution) is a member of the pyrrolo-pyrrole group of nonsteroidal anti-inflammatory drugs (NSAIDs) for ophthalmic use. Its chemical name is (±)-5-Benzoyl-2,3-dihydro-1<span class="Italics">H</span>-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) and it has the following structure:
						</p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5ba45168-ad5d-4ea9-bd85-fc2fa2b13dad&amp;name=acu02-0001-01.jpg">
</div>
<p><span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution is supplied as a sterile isotonic aqueous 0.5% solution, with a pH of 7.4. <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution is a racemic mixture of R-(+) and S-(-)- ketorolac tromethamine. Ketorolac tromethamine may exist in three crystal forms. All forms are equally soluble in water. The pKa of ketorolac is 3.5. This white to off-white crystalline substance discolors on prolonged exposure to light. The molecular weight of ketorolac tromethamine is  376.40. The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution is 290 mOsml/kg.
</p>
<p>Each mL of <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution contains: <span class="Bold">Active:</span> ketorolac tromethamine 0.5%. <span class="Bold">Preservative:</span> benzalkonium chloride 0.01%. <span class="Bold">Inactives:</span> edetate disodium 0.1%; octoxynol 40; purified water; sodium chloride; and hydrochloric acid and/or sodium hydroxide to adjust pH.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY
</h1>
<p class="First">Ketorolac tromethamine is a nonsteroidal anti-inflammatory drug which, when administered systemically, has demonstrated analgesic, anti-inflammatory, and anti-pyretic activity. The mechanism of its action is thought to be due to its ability to inhibit prostaglandin biosynthesis. Ketorolac tromethamine given systemically does not cause pupil constriction.
</p>
<p>Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>. In studies performed in animal eyes, prostaglandins have been shown to produce disruption of the blood-aqueous humor barrier, vasodilation, increased vascular permeability, <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>. Prostaglandins also appear to play a role in the miotic response produced during ocular surgery by constricting the iris sphincter independently of cholinergic mechanisms.
</p>
<p>Two drops (0.1 mL) of 0.5% <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution instilled into the eyes of patients 12 hours and 1 hour prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> extraction achieved measurable levels in 8 of 9 patients' eyes (mean ketorolac concentration 95 ng/mL aqueous humor, range 40 to 170 ng/mL). Ocular administration of ketorolac tromethamine reduces prostaglandin E<span class="Sub">2</span> (PGE<span class="Sub">2</span>) levels in aqueous humor. The mean concentration of PGE<span class="Sub">2</span> was 80 pg/mL in the aqueous humor of eyes receiving vehicle and 28 pg/mL in the eyes receiving <span class="Bold">ACULAR</span><span class="Sup">®</span> 0.5% ophthalmic solution.
</p>
<p>One drop (0.05 mL) of 0.5% <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution was instilled into one eye and one drop of vehicle into the other eye TID in 26 normal subjects. Only 5 of 26 subjects had a detectable amount of ketorolac in their plasma (range 10.7 to 22.5 ng/mL) at Day 10 during topical ocular treatment. When ketorolac tromethamine 10 mg is administered systemically every 6 hours, peak plasma levels at steady state are around 960 ng/mL.
</p>
<p>Two controlled clinical studies showed that <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution was significantly more effective than its vehicle in relieving <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> caused by seasonal <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.
</p>
<p>Two controlled clinical studies showed that patients treated for two weeks with <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution were less likely to have measurable signs of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (cell and flare) than patients treated with its vehicle.
</p>
<p>Results from clinical studies indicate that ketorolac tromethamine has no significant effect upon intraocular pressure; however, changes in intraocular pressure may occur following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.
</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE
</h1>
<p class="First"><span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution is indicated for the temporary relief of <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> due to seasonal <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>. <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution is also indicated for the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> extraction.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS
</h1>
<p class="First"><span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution is contraindicated in patients with previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients in the formulation.
</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>WARNINGS
</h1>
<p class="First">There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory agents. Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.
</p>
<p>With some nonsteroidal anti-inflammatory drugs, there exists the potential for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (including <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphemas</span>) in conjunction with ocular surgery.
</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s7"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="s8"></a><a name="section-6.1"></a><p></p>
<h2>General
</h2>
<p class="First">All topical nonsteroidal anti-inflammatory drugs (NSAIDs) may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
</p>
<p>Use of topical NSAIDs may result in <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> or <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs and should be closely monitored for corneal health.
</p>
<p>Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, ocular surface diseases (e.g., <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>), <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.
</p>
<p>Postmarketing experience with topical NSAIDs also suggests that use more than 24 hours prior to surgery or use beyond 14 days post-surgery may increase patient risk for the occurrence and severity of corneal adverse events.
</p>
<p>It is recommended that <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or who are receiving other medications which may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s9"></a><a name="section-6.2"></a><p></p>
<h2></h2>
<p class="First"><span class="Bold">Information for Patients: ACULAR</span><span class="Sup">®</span> ophthalmic solution should not be administered while wearing contact lenses.
</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s10"></a><a name="section-6.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Ketorolac tromethamine was not carcinogenic in rats given up to 5 mg/kg/day orally for 24  months (151 times the maximum recommended human topical ophthalmic dose, on a mg/kg basis, assuming 100% absorption in humans and animals) nor in mice given 2 mg/kg/day orally for 18 months (60 times the maximum recommended human topical ophthalmic dose, on a mg/kg basis, assuming 100% absorption in humans and animals).
</p>
<p>Ketorolac tromethamine was not mutagenic in vitro in the Ames assay or in forward mutation assays. Similarly, it did not result in an in vitro increase in unscheduled DNA synthesis or an in vivo increase in chromosome breakage in mice. However, ketorolac tromethamine did result in an increased incidence in chromosomal aberrations in Chinese hamster ovary cells.
</p>
<p>Ketorolac tromethamine did not impair fertility when administered orally to male and female rats at doses up to 272 and 484 times the maximum recommended human topical ophthalmic dose, respectively, on a mg/kg basis, assuming 100% absorption in humans and animals.
</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s11"></a><a name="section-6.4"></a><p></p>
<h2>Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s12"></a><a name="section-6.4.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic Effects: Pregnancy Category C.</span> Ketorolac tromethamine, administered during organogenesis, was not teratogenic in rabbits or rats at oral doses up to 109 times and 303 times the maximum recommended human topical ophthalmic dose, respectively, on a mg/kg basis assuming 100% absorption in humans and animals. When administered to rats after Day 17 of gestation at oral doses up to 45 times the maximum recommended human topical ophthalmic dose, respectively, on a mg/kg basis, assuming 100% absorption in humans and animals, ketorolac tromethamine resulted in dystocia and increased pup mortality. There are no adequate and well-controlled studies in pregnant women. <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
</p>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="e12"></a><a name="section-6.4.2"></a><p></p>
<p class="First"><span class="Bold">Nonteratogenic Effects:</span> Because of the known effects of prostaglandin-inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of <span class="Bold">ACULAR</span><span class="Sup">®</span>  ophthalmic solution during late pregnancy should be avoided.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s13"></a><a name="section-6.5"></a><p></p>
<h2>Nursing Mothers
</h2>
<p class="First">Caution should be exercised when <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s14"></a><a name="section-6.6"></a><p></p>
<h2>Pediatric Use
</h2>
<p class="First">Safety and efficacy in pediatric patients below the age of 3 have not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s15"></a><a name="section-6.7"></a><p></p>
<h2>Geriatric Use
</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s16"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS
</h1>
<p class="First">The most frequent adverse events reported with the use of ketorolac tromethamine ophthalmic solutions have been transient <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> and burning on instillation. These events were reported by up to 40% of patients participating in clinical trials.
</p>
<p>Other adverse events occurring approximately 1% - 10% of the time during treatment with ketorolac tromethamine ophthalmic solutions included <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>, ocular <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, ocular irritation, superficial <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, and superficial ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.
</p>
<p>Other adverse events reported rarely with the use of ketorolac tromethamine ophthalmic solutions included: <span class="product-label-link" type="condition" conceptid="4232690" conceptname="Infiltrate of cornea">corneal infiltrates</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulcer</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">eye dryness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbance</span> (<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurry vision</span>).
</p>
<div class="Section" data-sectionCode="34092-7">
<a name="s17"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">Clinical Practice:</span> The following events have been identified during postmarketing use of ketorolac tromethamine ophthalmic solution 0.5% in clinical practice. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. The events, which have been chosen for inclusion due to either their seriousness, frequency of reporting, possible causal connection to topical ketorolac tromethamine ophthalmic solution 0.5%, or a combination of these factors, include <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span> and epithelial breakdown (see <a href="#s8">PRECAUTIONS, General</a>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s18"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION
</h1>
<p class="First">The recommended dose of <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution is one drop (0.25 mg) four times a day for relief of <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span> due to seasonal <span class="product-label-link" type="condition" conceptid="374959" conceptname="Contact blepharoconjunctivitis">allergic conjunctivitis</span>.
</p>
<p>For the treatment of postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> in patients who have undergone <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> extraction, one drop of <span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution should be applied to the affected eye(s) four times daily beginning 24 hours after <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery and continuing through the first 2 weeks of the postoperative period.
</p>
<p><span class="Bold">ACULAR</span><span class="Sup">®</span> ophthalmic solution has been safely administered in conjunction with other ophthalmic medications such as antibiotics, beta blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics.
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s19"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED
</h1>
<p class="First"><span class="Bold">ACULAR</span><span class="Sup">®</span> (ketorolac tromethamine ophthalmic solution) is supplied sterile in opaque white LDPE plastic bottles with white droppers with gray high impact polystyrene (HIPS) caps as follows:
</p> 
5 mL in 10 mL bottle -  NDC 16590-002-05
<p>Store at 15°C - 25°C (59°F- 77°F) with protection from light.
</p>
<p><span class="Bold">Rx Only</span></p>
<p><span class="Bold">Revised: 05/2011</span></p>
<p>© 2011 Allergan, Inc.
</p>
<p>Irvine, CA 92612, U.S.A.
</p>
<p><span class="Bold">ACULAR</span><span class="Sup">®</span> is manufactured and distributed by Allergan, Inc. under license from its developer, Roche Palo Alto LLC, Palo Alto, CA, U.S.A.<br>® marks owned by Allergan, Inc.<br>Made in the U.S.A.</p>
<p><img alt="Logo
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5ba45168-ad5d-4ea9-bd85-fc2fa2b13dad&amp;name=acu02-0001-02.jpg"></p>
<p></p>
<p>71590US13C</p>
<p><span class="Bold">Relabeling and Repackaging by</span>:<br>STAT Rx USA LLC<br>Gainesville, GA  30501<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="j2"></a><a name="section-10"></a><p></p>
<p class="First"><span class="Bold"><br></span></p>
<p><span class="Bold">ACULAR® Rx only</span></p>
<p>(ketorolac tromethamine ophthalmic solution) 0.5%
</p>
<p>sterile <span class="Bold">5 mL</span></p>
<div class="Figure"><img alt="Label
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5ba45168-ad5d-4ea9-bd85-fc2fa2b13dad&amp;name=ACULAR%20SOL%20OPHTH%20.jpg"></div>
<br><br><span class="Bold"></span>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACULAR 		
					</strong><br><span class="contentTableReg">ketorolac tromethamine solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16590-002(NDC:0023-2181)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>KETOROLAC TROMETHAMINE</strong> (KETOROLAC ) </td>
<td class="formItem">KETOROLAC TROMETHAMINE</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>EDETATE DISODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>OCTOXYNOL-40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16590-002-05</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019700</td>
<td class="formItem">12/01/1992</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>STAT Rx USA LLC
							(786036330)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PSS World Medical Inc. (101822682)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">STAT Rx USA LLC</td>
<td class="formItem"></td>
<td class="formItem">786036330</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9b3dcaf1-1471-4f98-af83-2ea3fef6b3ca</div>
<div>Set id: 5ba45168-ad5d-4ea9-bd85-fc2fa2b13dad</div>
<div>Version: 4</div>
<div>Effective Time: 20120531</div>
</div>
</div> <div class="DistributorName">STAT Rx USA LLC</div></p>
</body></html>
